Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high
mortality, developing as a continuum, and progressing from the initial insult (underlying …

Cardiogenic shock is a high-acuity, potentially complex, and hemodynamically diverse state
of end-organ hypoperfusion that is frequently associated with multisystem organ failure …

Background The outcome of cardiogenic shock complicating myocardial infarction has not
appreciably changed in the last 30 years despite the development of various percutaneous …

Cardiogenic shock is a hemodynamically complex syndrome characterized by a low cardiac
output that often culminates in multiorgan system failure and death. Despite recent …

Inflammatory processes are firmly established as central to the development and
complications of cardiovascular diseases. Elevated levels of inflammatory markers have …

The recent widespread availability and use of mechanical circulatory support is transforming
the management and outcomes of cardiogenic shock (CS). Clinical decision-making …

Inflammation has been recognized as a major pathophysiological contributor to the entire
spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with …

Cardiogenic shock accounts for~ 100,000 annual hospital admissions in the United States.
Despite improvements in medical management strategies, in-hospital mortality remains …

Despite advances in coronary revascularization and widespread use of primary
percutaneous interventions, cardiogenic shock complicating an acute ST-elevation …

BACKGROUND: Trials of β blockers in patients undergoing non-cardiac surgery have
reported conflicting results. This randomised controlled trial, done in 190 hospitals in 23 …